Braveheart Bio reports Q2 2026 revenue of $0, EPS $(2.51), 10-Q
Braveheart Bio reported second-quarter 2026 revenue of $0 and EPS of $(2.51), with no product revenue and a wider net loss as late-stage development and trial activities ramped.
Story updates
08:14:03 PM UTC
SquawkNews
Braveheart Bio reported an unaudited net loss of $15.0 million for the quarter ended June 30, 2026, with cash and cash equivalents of $122.8 million at quarter-end (approximately $527.3 million on an as—adjusted basis after the August 2026 IPO). The company said its IPO proceeds are expected to fun…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.